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ABSTRACT
Purpose: Because we have found that random mucosal biopsies have no additional prognostic 
value to conventional histopathology, we studied biopsies of histologically normal bladder mu­
cosa with several molecular markers believed to be associated with the development of transi­
tional cell carcinoma.
Materials and Methods: Six groups of patients with an increasing stage of bladder tumor were 
selected: (1) benign disease (for example, benign prostatic hyperplasia, n = 8); (2-4) low (n = 10), 
intermediate (n = 9) and high risk (n = 7) superficial tumors; (5) progressive superficial tumors 
resistant to optimal conservative therapy (n = 6); (6) invasive or disseminated tumors at 
presentation (n = 5). We studied the expression of cytokeratin (used as an epithelial marker), 
fibronectin, E-cadherin (HECD-1), I-CAM, human leukocyte antigen (HLA)-I, HLA-II and epi­
dermal growth factor receptor (EGF-R) in cold-cup biopsies of normal mucosa.
Results: Fibronectin, HECD-1,1-CAM and HLA-II expression showed no significant changes in 
the different groups. There was a significant increase in the expression of HLA-I (p = .003) and 
EGF-R (p = .0001) with a higher stage of the tumor.
Conclusion: An increasing EGF-R expression in normal looking mucosa of patients with 
increasing stages of bladder tumors could be a prognostic factor or might indicate that this 
increase in expression is not tumor specific but is seen in the whole bladder.
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Of the patients presenting with transitional cell carcinoma 
(TCC) of the urinary bladder, approximately 65% have su­
perficial tumors (^pTl). The remaining patients present 
with invasive (^pT2) or metastatic (N+, M +) disease.1 Su­
perficial bladder cancer is characterized by inconsistent bio­
logical behavior. The risk of tumor recurrence and progres­
sion can vary. Of all superficial bladder cancer patients a 
small group will only have 1 episode of superficial tumor. 
After transurethral resection (TUR) they will be without 
recurrences with or without adjuvant treatment (“low risk 
tumors”). Another small group of patients will present with 
“high risk” tumors from the start. These patients are at risk 
for progression to invasive disease, despite maximal adju­
vant treatment. The majority of patients, however, will have 
regularly recurrent bladder tumors without obvious signs of 
progression (“intermediate risk”). To differentiate between 
these risk groups prognostic factors are used, such as tumor 
grade, stage, size and multiplicity, recurrence rate, and pos­
sibly the result of random mucosal biopsies. As we have 
shown, these selected mucosal biopsies are of no additional 
value to conventional histopathology in a multivariate anal­
ysis.2 However, the high recurrence rate and multiplicity in 
superficial bladder cancer suggest that the entire mucosa is 
primed to become malignant (field defect theory). Therefore, 
we looked at molecular changes in mucosal biopsies, using 
several markers associated with development of TCC. We 
analyzed normal-appearing mucosa in 6 groups of patients 
with an increasing stage and grade of bladder tumors. The 
expression of these markers in normal mucosa is believed to 
be a potential indicator of a mucosal field defect, and might
be an additional prognostic factor in the work-up of patients 
with bladder cancer.
Accepted for publication June 23, 1995.
* Requests for reprints: Department of Urology, University Hospi­
tal, Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
M A T E R IA L S  A N D  M E T H O D S
In all, 6 groups of patients were identified. For each group 
10 patients were selected (table 1). In every patient urethro- 
cystoscopy was done, and cold-cup mucosal biopsies were 
taken from normal-appearing mucosa. At least 2 biopsies 
were taken from the left and right lateral bladder wall. In 
case of a tumor on one of the lateral walls, the biopsy was 
taken 2 cm. away from the tumor. Biopsies were stored in 
liquid nitrogen. Serial frozen sections were obtained from the 
biopsy material. One section from each series for the immu- 
nohistochemical analysis was stained with hematoxylin and 
eosin to determine the histopathological diagnosis. In a pilot 
study we tested the feasibility of this technique, and the 
results showed that biopsies stored in this manner were 
adequate for these investigations. There were no artifacts 
due to storage in liquid nitrogen and there was little mechan­
ical damage,
We studied the expression of cytokeratin (CK18-2), fi­
bronectin, E-cadherin (HECD-1), intercellular adhesion mol­
ecule (I-CAM), human leukocyte antigen (HLA) class I, H LA  
class II and the epidermal growth factor receptor (EGF-R). 
The antigen G250, which is renal cell carcinoma specific with 
only minor expression on the major bile ducts, was used as a 
negative control. The monoclonal antibodies (MAbs) used for 
this testing are listed in table 2. Expression of the MAbs was 
tested by means of direct immunohis to chemical staining for 
MAbs for HLA  class I and II3 and indirect methods for the 
other MAbs. The indirect immunoperoxidase technique used 
in this study was performed at room temperature. The frozen 
sections were fixed with acetone for 10 minutes and air dried. 
Preincubation was done with 10% normal rabbit serum in
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Table 1. Risk groups of patients studied: tumor' stage, grade and primajy versus recurrent at time of biopsy indicated
Group Risk N Description with pathology at the time of biopsy
1 No risk 8 Patients with benign disease, e.g. prostatic hyperplasia
2 Low risk superficial 10 Patients with primary solitary pTa grade I (7) or Ha (3) tumors, remaining >1 
year disease free after TUR without adjuvant treatment
3 Intermediate risk superficial 9 Patients with pTa (5) or pTl (4) tumors, grade II (7) or III (2), recurrent (5) or 
primary (4), remaining >1 year disease free with adjuvant intravesical in­
stillations
4 High risk superficial 7 Patients with pTa (4) or pTl (3), grade II (6) or III (1), primary (2) or recur­
rent (5) tumors, with a superficial recurrence within 1 year in spite of addi­
tional therapy
5 Increasing risk 6 Patients with pTl (3) or in situ (3) tumors, grade II (1) or III (5), primary (2) 
or recurrent (4), having progression to muscle invasion or metastasis in 
spite of additional therapy
6 High risk 5 Invasive (2XpT2, lXpT3 and lXpT4) or disseminated disease (lxM +) at pri­
mary presentation
phosphate-buffered saline (PBS) for 30 minutes and subse­
quently with primary antibody for 1 hour. The primary an­
tibody concentration was typically determined by using se­
rial dilutions on a positive control. The optimal concentration 
was chosen as the lowest with which a clear positive signal was 
obtained at a minimal background. The optimal dilution is 
also indicated in table 2. After rinsing with PBS samples 
were incubated with horseradish peroxidase-conjugated rab­
bit anti-mouse immunoglobulin (Dakopatts A/S, Glostrup, 
Denmark) diluted 1:100 in PBS containing 1%  bovine serum 
albumin (BSA) for 30 minutes, and rinsed again with PBS 
before detection of the peroxidase activity with 3,3'-diamino- 
benzidine 0.6 mg./ml. (Sigma Chemical Co., St. Louis, Mis­
souri) in 0.65% imidazol/PBS containing 25 /xl. of 30% H 20 2. 
Following brief rinsing with water, the sections were incu­
bated with 0.5% CuS04 (in 0.9% NaCl) for 5 minutes to 
intensify the reactions. After rinsing with water, the sections 
were counterstained with hematoxylin, dehydrated and 
mounted. Control experiments were done with 1%  BSA in 
PBS instead of primary antibody.
Staining was scored semiquantitatively by 3 different in­
vestigators. For each antigen a total of 10 high-power fields 
was scored. In each high-power field the percentage of clearly 
positive staining cells was estimated, after determination of 
the optimal primary antibody concentration. No variations in 
intensity of staining were considered.
For statistical analysis of the 6 different groups of patients 
the Kendall test against rank-correlation was used.
RESULTS
First, conventional histology of the biopsies was studied. 
Only patients in whom this histology was normal, that is, 
without mucosal denudation, dysplasia or tumor, were eval­
uated. The remaining number of patients in each group was 
8 in group 1 (benign disease), 10 in group 2 (low risk), 9 in 
group 3 (intermediate risk), 7 in group 4 {high risk), 6 in group
5 (progressive superficial tumors in spite of optimal conser­
vative therapy) and 5 in group 6 (invasive or disseminated 
tumors at presentation).
The epithelial structures in the biopsy specimens were 
analyzed with the various antibodies. The results of the 
antibody expression, together with the results of the statis­
tical analysis are listed in table 3. G250 expression, used as 
a control for nonspecific staining, was negative in all cases.
The epithelial phenotype was confirmed by using cytokera­
tin 18 (CK18-2), an epithelial-specific intermediate filament 
protein that is known to be expressed in all cell layers of the 
mucosa. CK18-2 was chosen because the epitope recognized 
by this antibody is, unlike the one recognized by RGE53, not 
partially masked in normal urothelium. Although cytokera­
tin 18 expression was not used as a tumor marker, aberrant 
expression patterns have to be kept in mind in relation to 
stage and grade of TCC .4 In our study no significant changes
in CK18-2 expression were noted (p = .04) although expres­
sion decreased in the higher groups.
Evidence for gross changes in the extracellular matrix 
composition could result in changes in fibronectin (FN) stain­
ing, which is a component of the extracellular matrix. Dis­
ruption of the FN pattern and the subsequent decreased 
expression are associated with neoplastic changes in vitro.5 
We found no significant variation in either the pattern or 
intensity.
A  recently described progression marker is I-CAM class 1, 
even though its role has not been studied extensively in 
bladder cancer. There were no changes found in the expres­
sion of this protein in the various groups (p = .07).
A  protein that marks epithelial integrity is E-cadherin. 
E-cadherin expression is restricted to epithelial tissues6’7 
and is homogeneously; expressed in the urothelium at cell­
cell contacts.8 All biopsies in this study expressed E-cadherin 
homogeneously; hence no indication for microinvasive sub- 
populations was evident in any of the groups (p = .08).
Loss or decrease in the expression of histocompatibility 
antigens was reported for TCC and may be instrumental in 
escape from immune surveillance. Surprisingly, we found a 
significant increase in the expression of HLA I in the various 
groups (p = .003). Changes in expression of HLA II showed 
no significant differences between groups (p = .31).
A  well-described progression marker is EGF-R, which is 
normally expressed in the basal layers of the urothelium. 
Expression of EGF-R in both superficial and deeper layers of 
the mucosa, the so called malignant distribution, is associ­
ated with TCC .9 We found this malignant distribution of 
EGF-R in all patient groups and also in the mucosa of pa­
tients without bladder cancer. Statistical analysis showed a 
significant correlation between an increased EGF-R expres­
sion and a higher stage of the primary bladder tumor (p = 
.0001).
DISCUSSION
Because superficial bladder cancer is characterized by an 
unpredictable clinical course, prognostic factors are of partic­
ular interest. The high recurrence rate and multiplicity led 
some investigators to formulate a “field defect theory”, pre­
suming that carcinogenic factors in urine can affect the whole 
mucosa. Therefore, selected mucosal biopsies were believed 
to carry prognostic value. However, the value of histologic 
examination of mucosal biopsies of normal-appearing mucosa 
is contradictory and probably very limited.2 We investigated 
such biopsies with several markers, commonly used to study 
the development of TCC, in 6 groups of patients with tumors 
of increasing clinically malignant behavior. Of some mark­
ers, like cytokeratin 18 and fibronectin, little is known about 
the relation of the expression of these markers to TCC be­
havior, The relation of I-CAM expression and cancer has only 
been described recently. In kidney cancer an increased I-
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T a b l e  2 .  Monoclonal antibodies and their concentration used for
testing of the mucosal biopsies
Antigen Antibody* Dilution Reference
HLA I W.36.2 1:200 3
HLA II B8.11.2 1:200 3
E-Cadherin HECD-1 lO/xg./ml. 8
Cytokeratin CK18-2 1:2 4
Fibronectin MF1B 1:10 (Euro-Diagnostica, Apeldoorn,
» The Netherlands)
I-CAM P3,58BA-14:25 (Dr. J. Johnson, Inst, für Immunologie,
Univ. München, Germany)
EGF-R. RPN513 1:100 33
* Staining was done with rabbit-anti-mouse peroxidase, except fibronectin, 
which was stained with donkey-anti-goat peroxidase.
CAM expression is found compared with normal kidney tis­
sue.10 Such expression is also found in bladder cancer cell 
lines, and a relation was found between I-CAM class I ex­
pression and susceptibility for killer cells.11 Moreover, I-CAM 
expression was stimulated with interferon-gamma (IFN-y), 
indicating a possible mode of action of BCG, which increases 
urinary IFN-y. However, the relation between I-CAM expres­
sion and the prognosis of bladder cancer is unclear. Loss of 
E-cadherin expression or inhibition of E-cadherin by addition 
of antibodies is associated with invasive phenotype of several 
tumors.12-17 We found low E-cadherin expression to be asso­
ciated with invasive bladder cancer.8 Reduced expression of 
HLA-I has been described in various tumors18 and has been 
associated with the ability of tumor cells to escape immuno­
logic surveillance and with malignant potential (invasive­
ness, metastases, dedifferentiation) of the tumor, Cordon- 
Cardo et al., for example, found primary nonmetastatic 
lesions to be HLA-I positive in 8 of 11 patients, in contrast to 
33 of 44 metastatic lesions, which were negative.19 Normal 
bladder mucosa expresses HLA-I antigens.20 In bladder can­
cer, there is a reduced expression of HLA-I antigens with the 
change from dysplasia to tumor.21 Levin et al. found a sig­
nificant correlation of H LA I positive tumors and survival (p 
<0.05) and suggested that HLA-I expression is a prognostic 
indicator.18 However, the association between HLA antigens 
and TCC is not always clear, and may not be clinically rele­
vant.22 Only scant data on the relation between HLA-II ex­
pression and bladder cancer have been published and al­
though HLA-II expression was found in bladder cancer and 
correlated with BCG therapy23,24 and was induced by cyto­
kines,25 no correlation has been found between HLA-II ex­
pression and tumor aggressiveness.24,26
A  consistent value of the epidermal growth factor receptor 
(EGF-R) in TCC has been recently reported.9-27 Normally, 
EGF-R is found only on the basal layer of epithelial cells. In 
bladder tumors the urinary concentration of EGF can be 
decreased, but EGF-R expression in tumors is higher than in 
normal urothelium. Messing found increased expression of 
EGF-R in superficial and deeper layers of the mucosa (“ma­
lignant distribution”) in low and high grade TCC, as well as
in normal-appearing mucosa of patients with TCC elsewhere 
in the bladder.9 This might favor interaction of premalign ant 
and malignant mucosa with urinary EGF. Neal et al. studied 
101 patients with newly diagnosed bladder cancer, with a 
follow-up of 30 months.27 They found an association between 
strong positive immunohis to chemical staining of the EGF-R 
(48 tumors) and high stage bladder cancer (p <0.001). In pTa 
and pTl lesions (52 patients) EGF-R positivity was associ­
ated with multiplicity, short time to recurrence and high 
recurrence rate. In a multivariate analysis EGF-R positivity 
was predictive of bladder cancer related death in all 101 
patients (relative risk 3.42, p <0.001). In 52 patients with 
superficial TCC, EGF-R positivity was predictive for time to 
recurrence (relative risk 2.28, p <0.03) and time to progres­
sion (relative risk 22.12, p <0.001). For human bladder can­
cer cell lines transplanted into nude mice, a higher EGF-R 
expression was also found in the invasive cell lines than in 
the noninvasive lines.28
If the theory of a "field defect” is correct, premalignant 
abnormalities could be present in normal mucosa of bladder 
cancer patients.
Sidransky et al. examined 13 tumors from cystectomy spec­
imens from 4 women and found that, in each patient, all the 
tumors shared 2 chromosomal abnormalities (inactivation of 
the same X chromosome and loss of the same allele on chro­
mosome 9q).29 Loss of chromosome 17p and 18q was not the 
same in each patient, but these losses are late events in 
tumor progression. The authors concluded that these tumors 
arise from a single transformed cell after variable subse­
quent genetic alterations. This finding could indicate that, 
over time, (pre)malignant cells remain present in the bladder 
and can be detected. Similar findings about clonality of blad­
der tumors were published by Miyao et al., who found con­
cordance in loss of heterozygosity of chromosome 9 and 17p 
and p53 mutations between primary tumors and lymph node 
metastases in 14 patients.30 Flow cytometric measurement of 
DN A  ploidy of untreated bladder tumors and grossly normal 
distant bladder mucosa revealed comparable degrees of an- 
euploidy, also indicating the malignant potential of the nor­
mal mucosa.31 Rao et al. investigated biochemical markers in 
tumors, adjacent bladder mucosa and random distant blad­
der mucosa in 30 patients with superficial bladder tumors.32 
Although there was a decreasing degree of changes in most of 
these markers from the tumor to the distant mucosa, vari­
able degrees of marker changes in morphologically normal 
mucosa were present. G-actin, for example, was altered in 
58% of distant biopsy specimens in 30 patients compared 
with 0 in 6 normals. Abnormal EGF-R expression was found 
in ± 40% of the distant mucosal biopsies,
These data suggest that chromosomal and biochemical ab­
normalities can be present in normal-appearing mucosa. 
Therefore, investigation of normal-appearing mucosa re­
mains an interesting approach, with possible prognostic con­
sequences. The difference in our approach is that we com­
Table 3. Staining of antigens in mucosal biopsies: percentage (with range) of positive cells in high-power field.
Group HLA I HLA II HECD-1 CK18-2 FIBRO I-CAM EGFR
1 60 25 100 100 WK 30 70
(WK-100) (0-100) (10-80) (30-90)
2 20 7 100 100 WK 40 70
(10-30) (5-10) (20-70) (30-80)
3 35 7 100 100 WK 35 75
(5-80) (5-30) (90-100) • (0-50) (60-90)
4 30 <50 100 100 0 10 86
(WK-60) (0-5) (90-100) (90-100) (0-30) (70-90)
5 90 25 95 90 WK 25 90
(70-100) (5-90) (80-100) (80-100) (5-60) (87—90)
6 100 15 100 100 0 30 90
(5-50) (10-60) (75-95)
p -  .003 p = .31 p = 0.08 p = 0.04 p «  0.07 p = .0001.
* WK = weak staining.
In case antigen expression was seen, staining scored as positive (yes versus no). Differences in staining intensity were not considered. Statistican analysis 
+* irQ.nrlcill acra-msf. ran 1c-r».nrrft1 at.inn inot r»nsaihle for fibronectin).
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pared different groups of patients with an increasing stage of 
primary tumor. Looking at the markers we used, one might 
expect a rise in EGF-R expression and a fall in HLA  class I 
and E-cadherin expression with increasing malignant poten­
tial of the mucosa. The relation between H LA  class II, cyto- 
keratin, fibronectin and I-CAM expression and TCC behavior 
is inconsistent. The fact that most markers show no changes 
in our study indicates that normal mucosa in patients with 
bladder tumor reacts similarly to normal mucosa, and this 
does not support the “field defect” theory. The increasing 
HLA-I expression is the opposite of what was expected and is 
difficult to understand. Like others, we have found an abnor­
mal distribution of EGF-R expression (not only in basal cells) 
in normal-appearing mucosa,9 even in patients without his­
tological evidence of bladder carcinoma. However, the in­
creasing expression of EGF-R might indicate a malignant 
potential of the normal mucosa and might be of prognostic 
value. On the other hand, since this increased EGF-R expres­
sion especially is found in patients with invasive lesions, it 
might also indicate that increased EGF-R expression, which 
is believed to be associated with TCC progression, is a gen­
eral phenotypic change in the urothelium.
In conclusion, normal mucosa, adjacent to bladder tumors, 
harbors potential prognostic information. It is unclear 
whether or how this is related to the progression of transi­
tional cell carcinoma. Immunohistochemical examination of 
normal-appearing mucosa in bladder cancer patients with 
the markers presented here was not conclusive. Our results 
indicate that the expression of EGF-R in normal mucosa 
might be of value, but that unambiguous interpretation is not 
possible.
Acknowledgment The authors wish to thank Dr. W . Kir- 
kels for initiation of the project, Dr. A. Bierkens for assis­
tance with the clinical data and Anja de Ruyter and Peter 
van Stratum for technical assistance.
REFERENCES
1. Kiemeney, L. A, L> M., Witjes, J. A., Verbeek, A. L. 3VL, Heybroek,
R. P. and Debruyne, F. M. J.: The clinical epidemiology of 
superficial bladder cancer. Br. J. Cancer, 67: 806, 1993.
2. Witjes, J. A., Kiemeney, L. A. L. M., Verbeek, A. L. M.,
Heijbroek, R. P. and Debruyne, F, M, J.: Random bladder 
biopsies and the risk of recurrence in superficial bladder can­
cer, A prospective study in 1026 patients. World J. Urol., 10: 
231, 1992.
3. Beniers, A. J. M. C., Peelen, W. P., Debruyne, F. M. J. and
Schalken, J. A.: HLA-class-I and -class-II expression on renal 
tumor xenografts and the relation of sensitivity for alpha-IFN, 
gamma-IFN and TNF. Int. J, Cancer, 48: 709, 1991.
4. Schaafsma, H. A., Ramaekers, F. C. S., van Muijen, G. N. P.,
Robben, H., Lane, I. M,, Ooms, E. C. M., Schalken, J. A., van 
Moorselaar, R. J. A. and Ruiter, D. J.: Cytokeratin expression 
patterns in metastatic transitional cell carcinoma of the uri­
nary tract: an immunohisto chemical study comparing local 
tumor and autologous metastasis. Am. J. Clin. Pathol., 139: 
1389, 1991,
5. Reid, B. L. and Coppleson, M.: Carcinogenesis. Med. J. Aust,, 2:
5, 1983.
6. Behrens, J., Birchmeier, W., Goodman, S. L. and Imhof, B. A.:
Dissociation of Madin-Darby canine kidney epithelial cells by 
the monoclonal antibody anti-Arc-1: mechanistic aspects and 
identification of the antigen as a component related to uvo- 
morulin. J. Cell Biol., 101: 1307, 1985.
7. Shimoyama, Y., Hirohashi, S., Hirano, S., Noguchi, M.,
Shimosato, Y., Takeichi, M. and Abe, O.: Cadherin cell adhe­
sion molecules in human epithelial tissues and carcinomas. 
Cancer Res., 49: 2128, 1989.
8. Brinquier, P. P., Umbas, R. U,, Schaafsma, H. E., Karthaus,
H. F. M., Debruyne, F. M. J. and Schalken, J. A.: Decreased 
E-cadherin immunoreacitivity correlates with poor survival in 
patients with bladder tumors. Cancer Res., 53: 3241, 1993.
9. Messing, E. M.: Clinical implications of the expression of epider­
mal growth factor receptors in human transitional cell carci­
noma. Cancer Res., 50: 2530, 1990.
10. Tenabe, K., Klein, E., Alexander, J., Tubbs, R. and Finke, J.:
Expression, regulation and mediation of TIL-tumor interac­
tions by CD44 and CD 54 in renal cell carcinoma. J. Urol., 149: 
461 A, 1993.
11. Esuvaranathan, K., Jackson, A. M., Alexandrov, A. and James,
K: The expression of I-CAM 1 and I-CAM 2 in bladder cells. 
J. Urol., 149: 271A, 1993.
12. Behrens, J., Mar eel, M. M., Van Roy, F. M. and Brichmeier, W.:
Dissecting tumor cell invasion: epithelial cells acquire invasive 
properties after the loss of uvomorulin-mediated cell-cell ad­
hesion. J. Cell Biol., 108: 2435, 1989.
13. Frixen, U. H., Behrens, J,, Sachs, M., Eberle, G., Voss, B,,
Warda, A., Lochner, D. and Birchmeier, W.: E-cadherin-medi- 
ated cell-cell adhesion prevents invasiveness of human carci­
noma cells. J. Cell Biol., 113: 173, 1991.
14. Shimoyama, Y. and Hirohashi, S.: Cadherin intercellular adhe­
sion molecule in hepatocellular carcinomas: loss of E-cadherin 
expression in an undifferentiated carcinoma. Cancer Lett., 57: 
131, 1991.
15. Schipper, J. H., Frixen, U. H., Behrens, J., Unger, A., Jahnke, K.
and Birchmeier, W.: E-cadherin expression in squamous cell 
carcinomas of head and neck: inverse correlation with tumor 
dedifferentiation and lymph node metastasis. Cancer Res., 51: 
6328, 1991.
16. Bussemakers, M, J. G., Van Moorselaar, R. J. A., Giroldi, L. A,,
Ichikawa, T,, Isaacs, J. T., Takeichi, M., Debruyne, F. M. J. 
and Schalken, J. A.: Decreased expression of E-cadherin in the 
progression of rat prostate cancer. Cancer Res., 52:2916,1992.
17. Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S.,
Karthaus, H. F. M., Schaafsma, H, E., Debruyne, F. M. J, and 
Isaacs, W. B.: Expression of the cellular adhesion molecule 
E-cadherin is reduced or absent in high-grade prostate cancer. 
Cancer Res,, 52: 5104, 1992.
18. Levin, I., Klein, T., Goldstein, J., Kuperman, O., Kanetti, J. and
Klein, B,: Expression of class I histocompatibility antigens in 
transitional cell carcinoma of the urinary bladder in relation to 
survival. Cancer, 68: 2591, 1991.
19. Cordon-Cardo, C., Fuks, Z., Drobnjak, M., Moreno, C.,
Eisenbach, L. and Feldman, M.: Expression of HLA-A,B,C 
antigens on primary and metastatic tumor cell populations of 
human carcinomas. Cancer Res., 51: 6372, 1991.
20. Daar, A. S., Fuggle, S. V., Fabre, J. V., Ting, A. and Morris, P. J.:
The detailed distribution of HLA-ABC antigens in normal 
human organs. Transplantation, 38: 287, 1984.
21. Walton, G. R., McCue, P. A. and Graham, S. D,, Jr.; Beta-2-
microglobulins as a differentiation marker in bladder cancer.
J. Urol., 136: 1197, 1986.
22. Eryigit, M. and Kirkali, Z.: HLA antigens and transitional cell
carcinoma of the bladder. Urol. Int., 45: 75, 1990.
23. Prescott, S., James, K., Busuttil, A., Hargreave, T. B., Chisholm,
G. D, and Smyth, J. F.: HLA-DR expression by high grade 
superficial bladder cancer treated with BCG. Br. J. Urol., 63; 
264, 1989.
24. Stefanini, G. F., Bercovich, E., Mazzeo, V., Grigioni, W. F., Emili,
E., D’Errico, A., Lo Cigno, M., Tamagnini, N. and Mazzetti, M,: 
Class I and class II HLA antigen expression by transitional 
cell carcinoma of the bladder: correlation with T-cell infiltra­
tion and BCG treatment. J. Urol., 141: 1449, 1989.
25. Hawkyard, S. J., Jackson, A. M,, Prescott, S., James, K  and
Chisholm, G. D.: The effect of recombinant cytokines on blad­
der cancer cells in vitro. J. Urol., 150: 514, 1993.
26. Meyers, F. J., Gumerlock, P. H., Kawasaki, E. S., Wang, A. M.,
deVere White, R. W. and Erlich, H. A.: Bladder cancer: human 
leukocyte antigen II, interleukin-6, and interleukin-6 receptor 
expression determined by polymerase chain reaction. Cancer,
67: 2087, 1991.
27. Neal, D. E., Sharpies, L., Smith, K , Fennelly, J,, Hall, R. R. and
Harris, A. L.: The epidermal growth factor receptor and the 
prognosis of bladder cancer. Cancer, 65: 1619, 1990.
28. Theodorescu, D., Cornil, I., Sheenan, C., Man, M. S. and Kerb el,
R. S.: Ha-ras induction of the invasive phenotype results in 
up-regulation of epidermal growth factor receptors and altered
transitional cell carcinoma cells. Cancer Res., 51: 4486, 1991, 
29. Sidranski, D., Frost, P., Von Eschenbach, A., Oyasu, R., 
Preisinger, A. C. and Vogelstein, B.: Clonal origin of bladder 
cancer. N. Engl. J, Med., 326: 737, 1992.
PROGNOSTIC FACTORS IN BLADDER CANCER 2189
30. Miyao, N., Tsai, Y. C., Lerner, S. P., Olumi, A. F., Spruck, C. H.,
III, Gonzalez-Zulueta, M., Nichols, P. W., Skinner, D. G. and 
Jones, P. A.: Role of chromosome 9 in human bladder cancer. 
Cancer Res., 53: 4066, 1993.
31. Norming, U., Nyman, C. R. and Tribukait, B.: Comparative flow
cytometric deoxyribonucleic acid studies on exophytic tumor 
and random mucosal biopsies in untreated carcinoma of the 
bladder. J. Urol., 142: 1442, 1989.
32. Rao, J. Y., Hemstreet, R. E., Ill, Bonner, R. B., Jones, P. L., Min,
K. W. and Fradet, Y,: Alterations in phenotypic biochemical 
markers in bladder epithelium during tumorigenesis. Proc. 
Natl. Acad. Sci. U.S.A., 90: 8287, 1993.
33. Waterfield, M. D., Mayes, E. L., Stroobant, P., Remmet, P. L.,
Young, S., Goodfellow, P. N., Banting, G, S. and Ozanne, B.: A 
monoclonal antibody to the human epidermal growth factor 
receptor. J. Cell. Biochem., 20: 149, 1982.
